introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the presence of the Philadelphia chromosome (Ph + ), formed by a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11.2) [1] . Increased angiogenesis, the process of new blood vessel formation from endothelial precursors, has reported to be associated with the progression of CML [2] [3] [4] [5] . Recent studies indicated that imatinib mesylate (IM), a small molecule inhibitor with selective activity against BCR/ABL fusion tyrosine kinase, could reverse bone marrow angiogenesis and decrease the plasma concentration of vascular endothelial growth factor (VEGF) in CML patients [6] [7] [8] .
VEGF, a soluble, 34-46 kDa, heparin-binding glycoprotein dimer, is a potent angiogenic peptide with diverse biological activities including angiogenesis [9] . Vascular endothelial growth factor type A gene (VEGFA) expression is regulated by a variety of growth factors, cytokines, hormones and hypoxia [10] . Furthermore, recent investigations have demonstrated that VEGFA polymorphisms can contribute to the interindividual variants in VEGF expression. VEGFA is located on chromosome 6p21 and consists of eight exons and seven introns [11, 12] . The polymorphisms in the promoter region [loci 22578C>A (rs699947) and 2460T>C (rs833061)], 5#-untranslated region [+405C>G (rs2010963)] or 3#-untranslated region [+936C>T (rs3025039)] have been associated with different levels of VEGF expression [13] [14] [15] [16] [17] [18] .
Vascular endothelial growth factor receptor type 2 (VEGFR2), or kinase insert domain-containing receptor (KDR), consists of 1356 amino acids. VEGFR2 gene is located in 4q11-q12 and consisted of 26 exons. VEGFR2 plays a critical role in leukemia-associated angiogenesis [19] and transduces the major signals for angiogenesis via its strong tyrosine kinase activity [20] . VEGFR2 is expressed mostly on endothelial cells and in a fraction of hematopoietic stem cells [21] . VEGFR2 expression is also up-regulated by several folds in the tumor vasculatures. Autocrine or paracrine loop of VEGFA and VEGFR2 exists between tumor cells and vascular endothelial cells for the stimulation of angiogenesis [22, 23] . A recent study revealed that chronic phase (CP) CML patients with increased VEGFR2 levels had significantly inferior survival than patients without elevated VEGFR2 and indicated VEGFR2 overexpression as an independent prognostic indicator in CML patients [24] . Accordingly, the current study investigated the impact of four VEGF (VEGFA) and three VEGFR (VEGFR2) gene singlenucleotide polymorphisms (SNPs) on the treatment outcome of CML patients following IM therapy in 228 CML patients in terms of three parameters: (i) response to imatinib therapy [hematological response, major/complete cytogenetic response (MCyR/CCyR) and major/complete molecular response (MMoR/CMoR)]; (ii) treatment failure [loss of response (LOR) and primary resistance] and (iii) progression to accelerated phase (AP) or blast crisis (BC). [25, 26] . Two hundred and nine patients (92%) received IM at a starting dose of 400 mg/ day and 19 patients at starting dose of 600 mg/day (n = 17) or 800 mg/day (n = 2). All CP patients were started on 400 mg/day (n = 202), while patients in AP or BC started at doses of 400 mg/day (n = 7), 600 mg/day (n = 17) or 800 mg/day (n = 2). Treatment interruptions, dose adjustments and dose escalation were carried out as previously described [25, 27] .
patients' monitoring following IM therapy
Before commencing IM therapy, all patients had a complete blood cell count including white blood cell differential as well as standard biochemistry in addition to routine history taking and physical examination. Baseline tests also included bone marrow evaluation for morphology, conventional cytogenetic analysis and BCR/ABL messenger RNA (mRNA) RT-PCR. Patients were regularly monitored on an outpatient basis: biweekly physical examinations, blood counts and biochemistry were obtained during the first month of IM therapy and then monthly until a cytogenetic response was achieved and then every 3 months thereafter. Until a CCyR was confirmed, bone marrow evaluation and FISH studies were carried out every 3 months. The quantification of peripheral blood BCR/ABL fusion gene transcripts was repeated every 3 months regardless of cytogenetic response using quantitative BCR/ABL mRNA real-time quantitative PCR. Annual bone marrow evaluation with conventional cytogenetic analysis was carried out in order to detect clonal evolution.
Sequenom MassARRAY Genotyping system
Total of seven genotypes were selected for the analysis as previously described including four VEGFA genotypes: 22578C>A (rs699947), 2460T>C (rs833061), +405G>C (rs2010963) and +936 C>T (rs3025039) loci and three VEGFR2 genotypes: rs1531289, rs1870377 and rs2305948. Genotyping was undertaken using the SequenomÒ iPLEX platformä, according to the manufacturer's instructions (www.sequenom.com; Sequenom Inc., San Diego, CA). DNA was extracted using the Puregene DNA Purification Kit (Gentra Systems Inc., Minneapolis, MN). The detection of SNPs was carried out by the analysis of primer extension products generated from previously amplified genomic DNA using a Sequenom chip-based matrix-assisted laser desorption/ionization timeof-flight (MALDI-TOF) mass spectrometry platform. Multiplex SNP assays were designed using SpectroDesigner software (Sequenom). Ninety-six-well plates containing 2.5 ng DNA in each well were amplified by PCR following the specifications of Sequenom Inc. Unincorporated nucleotides in the PCR product were deactivated using shrimp alkaline phosphatase. Allele discrimination reactions were conducted by adding the extension primers, DNA polymerase and a cocktail mixture of deoxynucleotide triphosphates and di-deoxynucleotide triphosphates to each well. MassExtend clean resin (Sequenom Inc.) was added to the mixture to remove extraneous salts that could interfere with MALDI-TOF analysis. The primer extension products were then cleaned and spotted on to a SpectroChip (Sequenom Inc.). Genotypes were determined by spotting an aliquot of each sample on to a 384 SpectroChip, which was subsequently read by the MALDI-TOF mass spectrometer. Duplicate samples and negative controls were included to check genotyping quality. The primer sequences are summarized in the supplemental Table 1 (available at Annals of Oncology online).
BCR/ABL quantitative RT-PCR and tyrosine kinase domain mutation test
Peripheral blood samples (5 ml) were also analyzed to determine the levels of BCR/ABL fusion gene transcripts using quantitative PCR according to the manufacturer's instructions (ABI 9700 Thermal Cycler, Applied Biosystems, Foster City, CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as the control gene and BCR/ABL values were expressed as a logarithmic reduction from the baseline established by untreated 34 patients' BCR/ABL transcript levels before the commencement of IM. Nested RT-PCR techniques were used to confirm the results in selected samples that had undetectable BCR/ABL transcript levels. All blood samples were collected after informed consent had been obtained from patients in accordance with the Declaration of Helsinki.
definition of response criteria and end points
Response criteria for HR, MCyR and CCyR in the current study were the same as defined in other previous studies [25] [26] [27] [28] . Time-to-treatment failure was defined as the interval between the initiation of IM therapy and the occurrence of events, which indicated that patients had failed IM including primary hematological resistance, cytogenetic resistance or LOR. Time to LOR was defined as the interval between the date of any confirmed response and the date at which the criteria for response were no longer met, such as (i) transformation from CP to AP or BC, (ii) loss of CCyR/MCyR and (iii) confirmed increase of ‡1.0 log for patients in CCyR or more. Time to progression to AP or BC was defined as the interval between the initiation of IM therapy and confirmation of progression to AP or BC, while overall survival (OS) was calculated from the initiation of IM therapy until the date of death from any cause or the date of last follow-up.
statistical analysis
Seven SNPs were primarily evaluated for adequacy of Hardy-Weinberg equilibrium using chi-square test. The genotype frequencies were calculated using Haploview (available at http://www.broad.mit.edu/mpg/haploview). Additive, dominant and recessive models were applied to detect association between each SNP and treatment outcomes. Haplotype analysis was applied for neighboring SNPs with high linkage disequilibrium (LD). The individual haplotype and the haplotype frequencies were estimated based on a Bayesian algorithm using a program phase (available at http:// www.stat.washington.edu/stephens/phase.html) [29] .
The medical records including demographics and disease characteristics of all patients were reviewed until the end of December 2007. The cumulative incidences of MCyR, CCyR, MMoR and CMoR were calculated, while the probability of freedom from LOR and from treatment failure and of OS was estimated using the Kaplan-Meier method. In univariate analyses, the treatment outcomes such as MCyR, Additional cytogenetic findings were detected: 2Y (n = 5); double Ph + chromosome (n = 5); t(7;8) (n = 2); t(9;22;22) (n = 2); t(2;9;22) (n = 2); t(9;22;17)
(n = 1); t(1;22;18) with inv (5) (n = 1); t(7;8) with +8 and +der(22) (n = 1); t(8;17) (n = 1); t(8;16) (n = 1); inv (9q) (n = 1); 218q (n = 1); t(12;16) (n = 1); t(3;19) (n = 1); t(4;6), 47-52, +X, +6, +8, +18, +19, +der(22) (n = 1); t(17;20), +der (17) , +der (20) (n = 1); +8 (n = 1); 2X (n = 1 for the probability of progression to advanced disease. The multivariate analyses using Cox proportional hazard models were conducted using backward stepwise procedure. The hazard ratios (HRs) and 95% confidence intervals were also estimated.
To validate the genetic effect and other clinical factors, we carried out bootstrap algorithm based on 1000 replications and calculated the chance of selecting each variable in the 1000 stepwise procedures in the final model [30] . The bootstrap is one of resampling technique, and bootstrap datasets are created by sampling with replacement. The bootstrap method has been showed to provide valid estimation of prediction error and can correct for the bias of the parameter estimate. The results were carried out using PROC SURVERYSELECT procedure of SAS version 9.1 (SAS Institute, Cary, NC) and presented as the chance of accepting in the final multivariate model for the genetic effects and important clinical factors.
All statistical tests were two-sided with the significance level defined as 0.01. The statistical data were obtained using an SPSS software package (SPSS 13.0 Inc., Chicago, IL) and SAS version 9.1. The cumulative incidence curves were obtained using R package, version 2.4.1 (available at http://CRAN.R-project.org). results demographic and disease characteristics and treatment outcomes following imatinib therapy Baseline demographics and disease characteristics before commencement of IM therapy are summarized in Table 1 . Two hundred and two patients (89%) were in CP, 23 (10%) were in AP and three (1%) were in BC before the commencement of IM. In addition, there were no differences of demographics and disease characteristics according to the VEGFR2 or VEGFA haplotypes.
The median duration of IM administration was 40.7 months in all patients. In this cohort, the incidence of hematological response was 96% 6 3% at 3 months. The outcomes of imatinib therapy were as follows: 79% 6 3% of MCyR at 12 months, 63% 6 3% of CCyR at 12 months, 53% 6 4% of MMoR at 2 years and 33% 6 4% of CMoR at 3 years.
With median follow-up of 47.3 months, 74 cases (32%) of IM treatment failure were documented due to primary resistance (n = 14), LOR (n = 52) or intolerance to IM (n = 8).
The probabilities of freedom from treatment failure were 88% 6 2%, 74% 6 8% and 58% 6 4% at 1, 2 and 4 years, respectively, following IM therapy. Fifty-two cases (23%) of LOR were due to rising trend of BCR/ABL transcript (n = 30), loss of CCyR (n = 16) or progression to advanced disease (n = 6). The probabilities of freedom from LOR were 91% 6 2%, 78% 6 3% and 65% 6 4% at 1, 2 and 4 years, respectively, after any response to IM therapy had been attained. The 5-year probabilities of progression-free survival and of OS were 93% 6 2% and 95% 6 2%, respectively.
the genotype frequencies and its association with treatment outcomes following imatinib therapy
The genotype frequencies for seven genotypes are summarized in Table 2 . In single-marker analyses, strong correlations were noted between seven genotypes and the treatment outcome of IM therapy. There were strong associations of VEGFR2 SNPs (rs1531289 and rs1870377) with CCyR and of VEGFR2 SNP (rs1870377) with treatment failure. The group with AA genotype, VEGFR2 (rs1531289), showed a superior rate of CCyR to those with AG or GG genotype group (77% versus 61% at 12 months: P = 0.02; Figure 1A ), while the AA genotype group for VEGFR2 (rs1870377) showed better rate of CCyR than those with TA or AA genotypes (80% versus 60% at 12 months; P = 0.05; Figure 1B ). In addition, the AA genotype for VEGFR2 (rs1870377) showed higher rate of treatment failure-free rate at 2 years compared with those with TA or AA genotypes (90% versus 72%; P = 0.03; Figure 1C) .
With respect to VEGFA SNPs, significant correlations were noted between VEGFA SNP (rs3025039) and CMoR and VEGFA SNPs (rs699947 and rs833061) and progression to advanced disease ( Figure 1D and E). The AA genotype group for rs699947 or CC genotype group for rs833061 had higher risk of progression to advanced disease of 14% at 4 years, while other groups showed significantly lower risk of progression.
the haplotype analysis
The LDs of seven gene polymorphisms are shown in the supplemental Figure 1 (available at Annals of Oncology online). Strong LDs were noted among VEGFA SNPs: D# = 0.99 between rs699947 and rs833061; D# = 1.00 between rs699947 and rs2010963; D# = 0.98 between rs833061 and rs2010963 and in VEGFR2 SNP: D# = 0.95 between rs1531289 and rs1870377.
Three haplotypes of VEGFR2 gene for alleles of rs1531289 and rs1870377 were generated and analyzed as follows: GT (46.1%), AT (27.9%) and GA (25.7%). In addition, three of VEGFA haplotypes for alleles of rs699947, rs833061 and rs2010963 were generated and frequency was as follows: ACG (45.9%), CTC (32.0%) and CTG (21.5%).
In haplotype analyses, good correlations were found between VEGFR2 haplotype and CCyR, between VEGFR2 haplotype and treatment failure and between VEGFA haplotype and progression to advanced disease as shown in Tables 3 and 4 . The group with two copies of GA haplotype for VEGFR2 genes (rs1531289 and rs1870377) showed a higher rate of CCyR than those with zero or one copy of GA haplotype (80% versus 61%; P = 0.05; Figure 2A ). In terms of treatment failure, those with two copies of GA haplotype did well and their risk of treatment failure was much lower than those with zero or one copy of GA haplotype for VEGFR2 gene (probability of freedom from treatment failure; 90% versus 62%; P = 0.03; Figure 2B ). The ACG haplotype for VEGFA gene (rs699947, rs833061 and rs2010963) also could predict the risk of progression to Figure 2C . Due to selection bias issue, we carried out subgroup analyses confined to the patients newly diagnosed and received imatinib as a frontline therapy as shown in Table 3 . It have been reproduced that there are significant association of VEGFA SNP (rs699947) with progression, VEGFA SNP (rs833061) with progression, VEGFA haplotype with progression, VEGFR2 SNP (rs1531289) with CCyR, VEGFR2 SNP (rs1870377) with MCyR and VEGFR2 haplotype with MCyR (Table 3B) .
multivariate analysis
Multivariate analyses confirmed the findings from single-marker analyses or haplotype analyses (Table 5) . We repeated the multivariate analyses for each end point (i.e. CCyR, treatment failure and progression to AP/BC) incorporating genotype (model I) or haplotype information (model II). Our results indicated that strong correlations were revealed between (i) VEGFR2 SNPs and CCyR, (ii) VEGFR2 SNPs and treatment failure following IM therapy and (iii) VEGFA SNPs and progression to advanced disease.
internal validation using bootstrap method
The results of the bootstrap method are shown in Table 5 . We applied bootstrap based on 1000 replications. The result shows the probabilities of each variable to be accepted in the final multivariate model. In terms of the achievement of CCyR, as shown in Table 5 
discussion
The current study indicates that VEGFR2 gene may be associated with response or resistance to imatinib therapy, while VEGFA gene is a strong predictor for the progression of CML into advanced stage. First, significant associations of VEGFR2 SNPs were revealed with CCyR and with treatment failure following imatinib therapy; second, VEGFA SNPs and progression to advanced disease in CML patients. The group with two copies of GA haplotype for VEGFR2 gene, rs1531289 and rs1870377, showed a superior complete cytogenetic response to imatinib therapy compared with those with zero or one copy of GA haplotype. (B) The group with two copies of GA haplotype for VEGFR2 gene showed a higher probability of freedom from treatment failure (lower treatment failure) compared with those with zero or one copy of GA haplotype. (C) The group with two copies of ACG haplotype for VEGFA gene, rs699947, rs833061 and rs2010963, showed a higher risk of progression to advanced disease compared with those with zero or one copy of ACG haplotype.
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The clinical implication of increased vascularity in the marrow has been described in various hematological diseases including acute myeloid leukemia (AML), acute lymphoblastic leukemia, myelodysplastic syndrome or CML [3, 31] . The biological mechanism responsible for the angiogenic process and its clinical relevance needs to be fully defined in CML since angiogenesis-dependent growth pathway has been shown to be important in leukemogenesis. VEGF stimulates growth of vascular endothelium, thereby providing sufficient blood supply to feed growing leukemic cells.
In support of this, the VEGF expression levels were elevated in CML patients who progressed into advanced disease [4, 5] .
Furthermore, transfection of the BCR/ABL fusion oncogenes into hematopoietic cell lines resulted in the induction of VEGF [32, 33] , which implies that BCR/ABL fusion protein augments angiogenesis process either in a direct way or through microenvironmental factors in the marrow [34] . Dysregulated VEGF could facilitate leukemic growth or progression of AML in paracrine (via several growth factors) [35, 36] or autocrine pathways (via VEGFR2 on leukemic cells) [37, 38] .
In the current study, the VEGFA gene SNP was significantly correlated with the CML progression during imatinib therapy, which was independent of initial disease status at the start of imatinib. VEGFA is located on chromosome 6p21Á3 and consists of eight exons and seven introns [11, 12] . Our previous study of VEGFA SNP in AML showed that the VEGFA SNPs could predict the prognosis for AML patients, especially in terms of leukemia-free survival [39] . VEGFA gene SNPs could be a useful surrogate to predict the risk of progression into advanced CML disease. The haplotype analyses indicated a potential predictive role of the ACG haplotype of VEGFA gene SNP to identify high-risk patients who are likely to progress to advanced disease during IM therapy. Our results are in accordance with our previous study, which showed that AML patients with the CTG haplotype (counterpart of ACG haplotype) had better leukemia-free survival [39] , and with others which reported a strong correlation between overexpression of cellular VEGF with poor prognosis in CP CML [40] . Another important finding of the current study is that VEGFR2 gene SNP could be a surrogate to predict the response to imatinib therapy in terms of CCyR or treatment failure. However, it is not clear how VEGFR2 is involved in the action mechanism of IM therapy. VEGFR2 may play a critical role in sustaining the hematopoietic microenvironment based on the evidence of its high expression in human marrow, thus providing an ideal milieu for leukemic growth [41, 42] . It is probable that blockade of angiogenesis of VEGFR/KDRmediated pathway would be an alternative action mechanism of imatinib, although major effect of IM is inhibition of cellular proliferation and direct cell killing of CML cells. IM therapy not only blocks the endothelial cell expression BCR/ABL fusion genes but also reverses phosphorylation of VEGFR2/KDR, thus decreasing angiogenesis in the marrow [8] . The BCR/ABL fusion gene was detected in various proportions of endothelial cells generated from the bone marrow cells of CML patients [43] . Accordingly, it is plausible to hypothesize that the blockade of the BCR/ABL fusion gene by IM not only inhibits the leukemic growth of CML cell but also abrogates angiogenesis process of BCR/ABL-positive endothelial cells in the marrow. Ebos et al. [8] reported that conditioned media taken from p210-transfected cells could stimulate human umbilical vein endothelial cells by increasing phosphorylation of VEGFR2/KDR and the downstream serine/threonine kinase protein kinase B (PKB; also known as Akt), an important regulator of endothelial cell survival. Accordingly, interindividual variability of VEGFR2 gene or protein expression may affect the response to imatinib therapy.
Two SNPs were identified as important prognostic markers in the study (rs1531289 and rs1870377). The SNP for rs1531289 is located in intron, while that for rs1870377 is nonsynonymous SNPs substituting glycine with histidine (Q472H) [44] . Further study is warranted whether this nonsynonymous SNP correlates to phenotype of VEGFR2 on CML cells or marrow endothelial cells.
A potential debate is the use of GAPDH as control gene for determining BCR/ABL transcript level. GAPDH was used as internal control gene to monitor BCR-ABL transcript levels for past 7 years in our institute. And now it was switched to BCR as internal control gene. Our validation study showed that the log reduction difference by using GAPDH and BCR from 95% of patients is within 0.5 log (data not shown). Accordingly, internal and external reproducibility of measurement of BCR/ ABL transcript level was maintained in the current study.
More than 10 antagonists of VEGFR2, including kinase inhibitors and neutralizing antibodies, are now under clinical trials. Based on our results, it may be speculated that bevacizumab, which neutralizes soluble VEGF, may be effective in preventing CML progression to advanced disease during IM therapy [45] . Sorafenib or sunitinib, which blocks the tyrosine kinase activity of VEGFR2, might be good adjunctive agent, in combination with IM, in order to increase the CCyR rate or to prevent resistance to IM in CML patients [46] .
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